A new academic and commercial collaboration between The Institute of Cancer Research, the Bellvitge Biomedical Research Institute (Institut d’Investigació Biomèdica de Bellvitge, IDIBELL) and Vivan Therapeutics (My Personal Therapeutics Ltd.) seeks to create cancer drugs less prone to drug resistance, with a particular focus on drugs that could target KRAS.